dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Barbui, Tiziano |
dc.contributor.author | De Stefano, Valerio |
dc.contributor.author | Alvarez-Larran, Alberto |
dc.contributor.author | Iurlo, Alessandra |
dc.contributor.author | Masciulli, Arianna |
dc.contributor.author | Carobbio, Alessandra |
dc.contributor.author | Fox, Maria Laura |
dc.date.accessioned | 2021-06-09T11:01:29Z |
dc.date.available | 2021-06-09T11:01:29Z |
dc.date.issued | 2021-02-04 |
dc.identifier.citation | Barbui T, De Stefano V, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, et al. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. Blood Cancer J. 2021 Feb 4;11:21. |
dc.identifier.issn | 2044-5385 |
dc.identifier.uri | https://hdl.handle.net/11351/6042 |
dc.description | Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Malalties infeccioses; Malaltia mieloproliferativa; Factors de risc |
dc.description.sponsorship | The study was supported by a research grant by the COVID “3×1 project”, BREMBO S.p.A., Bergamo, Italy (T.B.) and by AIRC 5×1000 call “Metastatic disease: the key unmet need in oncology” to MYNERVA project, #21267 (MYeloid NEoplasms Research Venture AIRC). A detailed description of the MYNERVA project is available at https://progettomynerva.it (A.M.V., P.G.). The study was also supported by HARMONY PLUS, which is funded through the Innovative Medicines Initiative (IMI), Europe’s largest public–private initiative aiming to speed up the development of better and safer medicines for patients. The HARMONY Alliance has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. |
dc.language.iso | eng |
dc.publisher | Springer Nature |
dc.relation.ispartofseries | Blood Cancer Journal;11 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | COVID-19 (Malaltia) - Factors de risc |
dc.subject | Tromboembolisme |
dc.subject.mesh | Venous Thromboembolism |
dc.subject.mesh | Coronavirus Infections |
dc.subject.mesh | /complications |
dc.title | Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19 |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1038/s41408-021-00417-3 |
dc.subject.decs | tromboembolia venosa |
dc.subject.decs | infecciones por Coronavirus |
dc.subject.decs | /complicaciones |
dc.relation.publishversion | https://doi.org/10.1038/s41408-021-00417-3 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Barbui T, Masciulli A, Carobbio A] FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy. [De Stefano V] Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico “A. Gemelli” IRCCS, Rome, Italy. [Alvarez-Larran A] Hospital Clinic de Barcelona, Barcelona, Spain. [Iurlo A] Hematology Division, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy. [Fox ML] Servei d’Hematologia, Vall d’Hebron Institute of Oncology (VHIO), Barcelona Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 33563901 |
dc.identifier.wos | 000618326700001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |